Inogen (INGN) reported $349M in revenue for fiscal 2025, +3.9% year on year. That ranks #2411 by revenue among 2853 SEC filers and #239 in Healthcare. Net income was $22.7M, a net margin of 6.5%. Revenue has grown 16.4% a year on average since 2012 ($48.6M then). The fiscal 2025 balance sheet shows $299M in total assets, $104M in cash and $315,000 in long-term debt.
Key figures
| Key figures | FY2025 | YoY | Source |
|---|---|---|---|
| RevenueRevenues | $349M | +3.9% | FY20252025-12-31 |
| Gross profitGrossProfit | $154M | −0.3% | FY20252025-12-31 |
| Operating incomeOperatingIncomeLoss | −$30.2M | +$12.3M | FY20252025-12-31 |
| Net incomeNetIncomeLoss | $22.7M | −36.6% | FY20252025-12-31 |
| Operating cash flowNetCashProvidedByUsedInOperatingActivities | −$11.2M | −$17.1M | FY20252025-12-31 |
| Capital expenditurePaymentsToAcquirePropertyPlantAndEquipment | $2.5M | −24.9% | FY20252025-12-31 |
| Total assetsAssets | $299M | +0.8% | FY20252025-12-31 |
| Shareholders' equityStockholdersEquity | $192M | +10.6% | FY20252025-12-31 |
| CashCashAndCashEquivalentsAtCarryingValue | $104M | −8.8% | FY20252025-12-31 |
| Long-term debtLongTermDebt | $315,000 | 0.0% | FY20152015-12-31 |
Revenue is total net sales for the fiscal year, taken from each company's own annual filing.
Reported since the last full year
Three-month figures this company has filed since FY2025. A quarter is not comparable with a full year, and these figures are used nowhere else on the site: not in any ranking, not in comparisons, not in the download.
| Quarter | Revenue | Net income | Source |
|---|---|---|---|
| Q1 20262026-03-31 | $85.1M | −$8.3M | Open → |
| Q2 20262026-06-30 | $95.1M | −$3.9M | Open → |
Only periods that end on a calendar quarter appear here. A company whose fiscal year ends in June files on a different calendar, so it has no row.
Profile
- Legal name
- Inogen Inc
- Ticker
- INGN
- Exchange
- Nasdaq
- SIC classification
- Orthopedic, Prosthetic & Surgical Appliances & Supplies (3842)
- Fiscal year end
- 12-31
- CIK
- 0001294133
Filings
- 10-QAug 7, 2026Open filing →
- 10-QMay 8, 2026Open filing →
- 10-KFeb 27, 2026Open filing →
Similar in size, same sector
| Company | Revenue | Net income |
|---|---|---|
| Arcutis BiotherapeuticsARQT | $376M | −$16.1M |
| InmodeINMD | $370M | $93.8M |
| MannkindMNKD | $349M | $5.9M |
| InogenINGN | $349M | $22.7M |
| Castle BiosciencesCSTL | $344M | −$24.2M |
| Tactile Systems TechnologyTCMD | $330M | $19.1M |
| Fulgent GeneticsFLGT | $323M | −$60.5M |
Cite this page
Ready-made references for the figures on this page, as published on September 25, 2026.
Wikipedia
{{cite web |title=Inogen — Key figures |url=https://companiesranked.com/en/company/inogen |website=CompaniesRanked |date=2026-09-25 |language=en}}APA 7
CompaniesRanked. (September 25, 2026). Inogen — Key figures. CompaniesRanked. https://companiesranked.com/en/company/inogenBibTeX
@misc{companiesranked-en-company-inogen-2026,
author = {{CompaniesRanked}},
title = {{Inogen — Key figures}},
year = {2026},
howpublished = {\url{https://companiesranked.com/en/company/inogen}},
note = {Compiled from SEC EDGAR XBRL filings; data as of 2026-09-25},
urldate = {2026-09-25}
}The filing itself
The numbers above are read from this document: 10-K · 0001193125-26-082630 · February 27, 2026
{{cite web |title=Inogen — Key figures — 10-K (0001193125-26-082630) |url=https://www.sec.gov/Archives/edgar/data/1294133/000119312526082630/ingn-20251231.htm |website=SEC EDGAR |publisher=U.S. Securities and Exchange Commission |date=2026-02-27}}The figures are rebuilt with every data refresh, so the reference carries the publication date. Add your own access date if your style requires one.